Lipanthyl Supra (Fenofibrate Micronised)

Fenofibrate activates the nuclear receptor PPARα, which regulates genes involved in fatty‑acid oxidation and lipoprotein metabolism. By enhancing the breakdown of triglyceride‑rich particles and reducing hepatic VLDL production, it lowers plasma triglycerides and modestly raises HDL‑cholesterol, improving the overall lipid profile.

The appropriate dose of Lipanthyl Supra is individualized by the prescribing healthcare professional based on the patient’s specific lipid profile, renal and hepatic function, and any concomitant medications. The prescriber will select the dose that best balances efficacy with safety for each patient.

The safety of fenofibrate during pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful assessment.

To request Lipanthyl Supra, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled logistics) and the necessary import documentation.

Lipanthyl Supra belongs to the fibrate class, which primarily lowers triglycerides, whereas statins are the main alternative class that primarily reduce LDL‑cholesterol. Fibrates are often added to statin therapy when triglycerides remain high. Compared with gemfibrozil, fenofibrate generally has a more favorable safety profile and fewer drug‑interaction concerns.

Lipanthyl Supra should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Lipanthyl Supra is taken orally, usually once daily with a meal to improve absorption. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious adverse events associated with fenofibrate include rhabdomyolysis (severe muscle breakdown that can lead to kidney failure) and significant liver injury such as hepatitis or hepatic failure. Patients should promptly report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction such as jaundice.

Lipanthyl Supra is contraindicated in patients with known hypersensitivity to fenofibrate or any component of the formulation, severe liver disease, active gallbladder disease, and in individuals with a history of rhabdomyolysis. Caution is also advised for patients with renal impairment, and it should be avoided in combination with certain interacting drugs such as gemfibrozil.